Spermosens Competitors

9R5 Stock

0 0.0006 33.33%

Spermosens AB competes with WuXi AppTec, Thermo Fisher, Danaher, Danaher, and Siemens Healthineers; as well as few others. The company classifies itself under Healthcare sector and is part of Diagnostics & Research industry. Analyzing Spermosens competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Spermosens to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Spermosens Correlation with its peers.

Spermosens vs Koninklijke Philips Correlation

Modest diversification

The correlation between Spermosens AB and PHI1 is 0.28 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Spermosens AB and PHI1 in the same portfolio, assuming nothing else is changed.

Moving against Spermosens Stock

0.6	SHL	Siemens Healthineers	Pair Corr
0.58	SHL1	SIEMENS HEALTH ADR050	Pair Corr
0.55	DAP	Danaher	Pair Corr
0.51	DAP	Danaher	Pair Corr
0.35	TN8	Thermo Fisher Scientific	Pair Corr

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.00	0	50.09

Details

Intrinsic

Valuation

Low	Real	High
0.00	0	50.09

Details

Spermosens Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Spermosens and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Spermosens and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Spermosens AB does not affect the price movement of the other competitor.

	WX8	TN8	DAP	DAP	SHL	SHL1	IX1	AG8	WAZ	PHI1
WX8		-0.1	0.0	-0.09	-0.02	0.05	-0.33	-0.43	-0.4	0.74	WX8
TN8	-0.1		0.83	0.88	0.58	0.59	0.59	0.59	0.73	-0.07	TN8
DAP	0.0	0.83		0.92	0.6	0.61	0.59	0.48	0.7	-0.14	DAP
DAP	-0.09	0.88	0.92		0.65	0.63	0.6	0.57	0.69	-0.14	DAP
SHL	-0.02	0.58	0.6	0.65		0.83	0.27	0.29	0.39	0.02	SHL
SHL1	0.05	0.59	0.61	0.63	0.83		0.24	0.16	0.38	0.04	SHL1
IX1	-0.33	0.59	0.59	0.6	0.27	0.24		0.82	0.8	-0.32	IX1
AG8	-0.43	0.59	0.48	0.57	0.29	0.16	0.82		0.7	-0.25	AG8
WAZ	-0.4	0.73	0.7	0.69	0.39	0.38	0.8	0.7		-0.39	WAZ
PHI1	0.74	-0.07	-0.14	-0.14	0.02	0.04	-0.32	-0.25	-0.39		PHI1
	WX8	TN8	DAP	DAP	SHL	SHL1	IX1	AG8	WAZ	PHI1

Please upgrade your account to get full access to Macroaxis premium features

High positive correlations

DAP	+ 0.92	DAP
DAP	+ 0.88	TN8
DAP	+ 0.83	TN8
SHL1	+ 0.83	SHL
AG8	+ 0.82	IX1
WAZ	+ 0.8	IX1

High negative correlations

AG8	- 0.43	WX8
WAZ	- 0.4	WX8
PHI1	- 0.39	WAZ
IX1	- 0.33	WX8
PHI1	- 0.32	IX1
PHI1	- 0.25	AG8

Risk-Adjusted Indicators

There is a big difference between Spermosens Stock performing well and Spermosens Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Spermosens' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
WX8	1.97	0.23	0.09	1.17	1.76	(2.74)	4.46	(2.75)	12.46
TN8	1.45	(0.24)	0.00	1.87	0.00	0.00	3.66	(3.60)	8.38
DAP	1.01	(0.01)	(0.02)	0.02	1.62	(0.89)	2.00	(2.31)	7.88
DAP	1.19	(0.09)	0.00	0.38	0.00	0.00	1.99	(2.80)	9.06
SHL	1.03	(0.11)	0.00	(0.31)	0.00	0.00	1.65	(2.09)	5.93
SHL1	1.56	(0.09)	0.00	0.49	0.00	0.00	2.83	(4.52)	8.50
IX1	1.31	(0.22)	0.00	(0.61)	0.00	0.00	2.57	(3.22)	13.60
AG8	1.32	(0.31)	0.00	4.03	0.00	0.00	3.15	(2.66)	8.21
WAZ	1.43	(0.24)	0.00	(1.21)	0.00	0.00	2.91	(2.97)	18.26
PHI1	1.38	0.08	0.02	0.81	1.74	(1.56)	2.37	(2.72)	17.60

Spermosens Competitive Analysis

The better you understand Spermosens competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Spermosens' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Spermosens' competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	9R5	WX8	TN8	DAP	DAP	SHL	SHL1	IX1	AG8	WAZ
	33.33 0 Spermosens	1.52 13.00 WuXi	0.62 427.65 Thermo	3.72 174.74 Danaher	2.99 173.52 Danaher	0.20 40.94 Siemens	1.01 20.00 SIEMENS	0.11 529.00 IDEXX	1.18 104.20 Agilent	0.59 270.10 Waters
Market Volatility (90 Days Market Risk)	Out of control	Not too volatile	Very steady	Very steady	Very steady	Very steady	Not too volatile	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Solid	Mild	Weakest	Weakest	Weakest	Soft	Weak	Weakest	Weakest	Weakest
Odds of Financial Distress (Probability Of Bankruptcy)	High	Tiny	Low	Tiny	Low	Low	Low	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Fairly Valued	Over Valued	Fairly Valued	Over Valued	Fairly Valued	Over Valued	Over Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Hold	Strong Buy	Strong Sell	Cautious Hold	Strong Sell	Strong Hold	Strong Sell	Hold	Sell	Hold
Current Ratio	N/A	2.61	1.5	N/A	2.26	1.13	1.13	1.01	3.41	3.44
Net Asset	31.04 M	80.33 B	97.32 B	83.47 B	77.54 B	49.06 B	N/A	3.29 B	12.73 B	4.55 B
Profit Margin	N/A	0.34	0.15	0.15	0.15	0.091	0.091	0.25	0.19	0.2
EBITDA	(9.28 M)	18 B	11.15 B	6.95 B	7.14 B	4.05 B	4.05 B	1.5 B	1.96 B	1.12 B
Current Valuation	803.27 K	282.82 B	184.49 B	138.26 B	138.26 B	43.87 B	43.87 B	42.91 B	31.3 B	27.42 B
Price To Book	0.2	0.56	3.55	2.89	2.86	2.49	2.42	30.58	5.25	12.28
Operating Margin	N/A	0.38	0.2	0.22	0.22	0.13	0.13	0.29	0.26	0.34
Retained Earnings	(91.57 M)	32.01 B	53.1 B	46.89 B	44.19 B	N/A	N/A	5.33 B	1.39 B	9.79 B
Five Year Return	N/A	N/A	0.34	N/A	0.49	N/A	N/A	N/A	0.87	N/A
Beta	-0.25	0.62	0.95	0.96	0.96	0.82	0.82	1.66	1.3	1.18
Number Of Employees	4	39.41 K	125 K	60 K	60 K	73.8 K	73.8 K	11 K	18.1 K	7.9 K
Shares Outstanding	3.17 B	510.48 M	375.71 M	706.9 M	706.9 M	1.12 B	2.23 B	79.85 M	282.84 M	98.09 M
Cash Flow From Operations	(7.76 M)	12.41 B	8.67 B	6.4 B	6.69 B	2.83 B	3.21 B	929 M	1.56 B	762.12 M
Annual Yield	N/A	0.0735	0.0035	0.0059	0.006	0.0244	0.0252	N/A	0.0081	N/A
Total Debt	230 K	1.24 B	2.21 B	18.42 B	505 M	93 M	14.88 B	417.79 M	304 M	2.73 B
Return On Equity	-0.34	0.26	0.13	0.0705	0.0705	0.11	0.11	0.66	0.21	0.29
Return On Asset	-0.19	0.11	0.0504	0.0364	0.0364	0.0425	0.0425	0.26	0.0849	0.12
Book Value Per Share	0.011	3.02	119.89	62.63	62.72	16.42	16.42	16.93	20.07	36.3
Total Asset	31.04 M	80.33 B	97.32 B	83.47 B	77.54 B	49.06 B	N/A	3.29 B	12.73 B	4.55 B
Debt To Equity	N/A	0.11	68.7	N/A	0.48	0.97	0.97	N/A	35.0	128.4
Last Dividend Paid	N/A	1.33	1.72	1.28	1.28	1.0	1.0	N/A	0.99	N/A
Target Price	N/A	N/A	N/A	N/A	331.45	55.42	N/A	707.0	N/A	361.75
Shares Owned By Institutions	N/A	61.27	92.44	83.6	83.6	13.16	N/A	99.31	91.61	60.22
Market Capitalization	634.6 K	355.29 B	160.67 B	123 B	122.66 B	45.72 B	44.23 B	42.29 B	29.51 B	25.77 B
Price To Earning	N/A	82.51	28.78	N/A	48.79	34.79	38.03	57.45	18.31	24.85
Price To Earnings To Growth	N/A	N/A	1.86	2.02	1.99	1.41	1.38	3.65	1.69	3.55
Price To Sales	N/A	8.1	3.61	5.01	4.99	1.96	1.9	9.83	4.25	8.14
Net Income	(10.2 M)	9.45 B	6.33 B	3.6 B	3.9 B	1.94 B	1.69 B	887.87 M	1.3 B	637.83 M
Earnings Per Share	N/A	5.23	14.96	4.25	4.24	1.89	0.94	11.03	3.85	9.08
Shares Owned By Insiders	N/A	12.76	0.15	11.05	11.05	67.0	N/A	0.69	0.18	0.1
Revenue	N/A	39.24 B	42.88 B	24.57 B	23.88 B	22.36 B	23.3 B	3.9 B	6.95 B	2.96 B
Working Capital	(1.94 M)	22.46 B	8.8 B	N/A	2.7 B	N/A	N/A	331.98 M	2.25 B	879.35 M
Cash And Equivalents	N/A	12.79 B	2.29 B	N/A	7.32 B	1.47 B	1.47 B	116.62 M	2.16 B	1.17 B
Cash Per Share	N/A	4.35	5.71	N/A	10.26	1.32	0.66	1.36	6.82	16.8
Gross Profit	N/A	20.15 B	18.57 B	14.52 B	14.52 B	8.95 B	8.95 B	2.66 B	3.64 B	1.88 B
Day Typical Price	0.0013	13.0	426.58	172.81	172.16	40.89	20.0	529.0	104.47	270.2
Accumulation Distribution	0.25	N/A	0.0075	116.47	0.0558	0.0083	N/A	N/A	0.0107	0.0011
Market Facilitation Index	4.0E-4	N/A	3.2	0.0063	9.84	0.34	N/A	N/A	1.12	0.3
Daily Balance Of Power	(1.50)	0	0.8281	(0.59)	(0.54)	(0.24)	9.2 T	0	(1.11)	(5.33)
Period Momentum Indicator	(0.0006)	(0.20)	2.65	(6.76)	(5.34)	(0.08)	0.2	(0.60)	(1.24)	(1.60)
Rate Of Daily Change	0.67	0.98	1.01	0.96	0.97	1.0	1.01	1.0	0.99	0.99
Day Median Price	0.0014	13.0	426.05	171.85	171.48	40.87	20.0	529.0	104.6	270.25
Price Action Indicator	(0.0005)	(0.10)	2.92	(0.49)	(0.63)	0.03	0.1	(0.30)	(1.02)	(0.95)
Coefficient Of Variation	495.82	1050.73	(808.46)	10596.56	(1,751)	(1,489)	(2,367)	(1,043)	(571.70)	(1,071)
Mean Deviation	59.5	1.97	1.45	1.01	1.19	1.03	1.56	1.31	1.32	1.43
Jensen Alpha	27.27	0.2258	(0.24)	(0.01)	(0.09)	(0.11)	(0.09)	(0.22)	(0.31)	(0.24)
Total Risk Alpha	20.17	0.0954	(0.35)	(0.07)	(0.18)	(0.17)	(0.21)	(0.32)	(0.41)	(0.36)
Sortino Ratio	N/A	0.0869	N/A	(0.02)	N/A	N/A	N/A	N/A	N/A	N/A
Downside Variance	N/A	4.86	N/A	2.75	N/A	N/A	N/A	N/A	N/A	N/A
Standard Deviation	136.76	2.57	1.89	1.38	1.55	1.35	2.04	2.06	1.75	2.35
Kurtosis	22.26	1.97	0.1876	1.68	1.64	1.45	(0.09)	6.66	0.7352	17.58
Potential Upside	400.0	4.46	3.66	2.0	1.99	1.65	2.83	2.57	3.15	2.91
Treynor Ratio	3.97	1.17	1.87	0.0159	0.3804	(0.31)	0.487	(0.61)	4.03	(1.21)
Maximum Drawdown	480.0	12.46	8.38	7.88	9.06	5.93	8.5	13.6	8.21	18.26
Variance	18702.26	6.6	3.59	1.9	2.42	1.81	4.15	4.24	3.07	5.52
Market Risk Adjusted Performance	3.98	1.18	1.88	0.0259	0.3904	(0.30)	0.497	(0.60)	4.04	(1.20)
Risk Adjusted Performance	0.1703	0.0826	(0.09)	0.0117	(0.04)	(0.05)	(0.03)	(0.07)	(0.13)	(0.07)
Skewness	4.56	1.05	0.1743	(0.73)	(0.59)	(0.96)	(0.58)	1.64	0.5452	(2.98)
Semi Deviation	N/A	1.76	N/A	1.62	N/A	N/A	N/A	N/A	N/A	N/A
Information Ratio	0.2013	0.0745	(0.15)	(0.03)	(0.09)	(0.11)	(0.07)	(0.12)	(0.21)	(0.12)
Value At Risk	(33.33)	(2.75)	(3.60)	(2.31)	(2.80)	(2.09)	(4.52)	(3.22)	(2.66)	(2.97)
Expected Short fall	N/A	(2.74)	N/A	(0.89)	N/A	N/A	N/A	N/A	N/A	N/A
Downside Deviation	N/A	2.2	N/A	1.66	N/A	N/A	N/A	N/A	N/A	N/A
Semi Variance	N/A	3.11	N/A	2.64	N/A	N/A	N/A	N/A	N/A	N/A

Spermosens Competition Performance Charts

Five steps to successful analysis of Spermosens Competition

Spermosens' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Spermosens AB in relation to its competition. Spermosens' competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Spermosens in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Spermosens' competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Spermosens AB, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Spermosens position

In addition to having Spermosens in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Iron Thematic Idea Now

Iron

Companies involved in production of steel and iron. The Iron theme has 47 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in Spermosens Stock

Spermosens financial ratios help investors to determine whether Spermosens Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spermosens with respect to the benefits of owning Spermosens security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Spermosens Competitors

Spermosens vs Koninklijke Philips Correlation

Modest diversification

Moving against Spermosens Stock

Specify up to 10 symbols:

Spermosens Competition Correlation Matrix

High positive correlations

High negative correlations

Risk-Adjusted Indicators

Spermosens Competitive Analysis

Spermosens Competition Performance Charts

Five steps to successful analysis of Spermosens Competition

Complement your Spermosens position

Did You Try This Idea?

Run Iron Thematic Idea Now

Iron

Other Information on Investing in Spermosens Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY